Asia-Pacific

On August 28 2020, the Chinese Supreme People's Court (SPC) granted the very first anti-suit injunction in the standard essential patent (SEP) royalty dispute case of Huawei v Conversant, which enjoined Conversant Wireless Licensing (Conversant) from seeking enforcement of the Dusseldorf regional court's injunction ruling against Huawei Technologies (Huawei). This case thus opened the door for Chinese courts to issue anti-suit injunctions (ASIs).

In the midst of a pandemic that has disrupted economic activity so much so that Indonesia recently entered its first recession in over two decades, a proposed law on job creation brought thousands of protesters out to Jakarta's now almost deserted streets. The law weakens worker and environmental protections in the name of increasing business ease and underwent a somewhat unconventional and confusing path to implementation (there were four separate final drafts circulating at one point with differences of hundreds of pages). As a result, the law has been controversial from beginning to end. In its final form, it is over 1,100 pages long and amends approximately 75 separate laws, packaged together as the Job Creation Law No. 11 of Year 2020 or just the Omnibus Bill.

The Working Statement which patentees need to file every year continues to be a controversial subject. The frequent changes in the forms and varying stands of the patent office have added to the confusion.

A recent trademark decision by the Intellectual Property Office of New Zealand (IPONZ) reveals the importance of submitting reliable and probative evidence in invalidation proceedings, even when the invalidation proceedings are undefended by the trademark owner.

Artificial intelligence (AI) is a technology that simulates human intelligence. It performs tasks that usually require human intelligence, such as visual perception, natural speech recognition and language translation.

Amid the coronavirus pandemic, pioneering pharmaceutical makers, research institutes, and universities are working in collaboration to develop novel antiviral drugs that are small compounds and vaccines. Although most inventions produced this year will be disclosed when their patent applications are published next year, the inventions being developed before this pandemic have already been disclosed.